Veracyte VCYT Biopharmaceutical and other revenue — Accounts receivable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
Accounts receivable from biopharmaceutical and other revenue was $1.1 million at March 31, 2026 and $3.6 million at December 31, 2025. Deferred revenue related to these agreements was $0.7 million at March 31, 2026 and $1.2 million at December 31, 2025. Following the restructuring proceedings affecting Veracyte SAS, as of August 2025 Veracyte SAS no longer provides biopharmaceutical services, contract manufacturing or contract development services. Revenue included in biopharmaceutical and other revenue for the three months ended March 31, 2026 and 2025 was as follows (in thousands of dollars):
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's biopharmaceutical and other revenue — accounts receivable?
- Veracyte (VCYT) reported biopharmaceutical and other revenue — accounts receivable of $1.1M in Q1 2026.
- How has Veracyte's biopharmaceutical and other revenue — accounts receivable changed year-over-year?
- Veracyte's biopharmaceutical and other revenue — accounts receivable decreased by 78.4% year-over-year, from $5.1M to $1.1M.
- What is the long-term trend for Veracyte's biopharmaceutical and other revenue — accounts receivable?
- Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — accounts receivable has grown at a -24.4% compound annual growth rate (CAGR), from $35.4M to $15.3M.
- What does biopharmaceutical and other revenue — accounts receivable mean?
- This metric represents the outstanding payments owed to the company by biopharmaceutical partners and research clients for services already rendered. It is a critical measure of the company's liquidity and the effectiveness of its credit and collection policies regarding its B2B service segment.
Ask your AI about Veracyte's biopharmaceutical and other revenue — accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
